跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
獎項
活動
新聞/媒體
設備
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
楊 展庚
臨床助理教授
,
醫學系
電子郵件
D000019779
cgu.edu
tw
h-index
h10-index
h5-index
210
引文
10
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
203
引文
10
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
89
引文
5
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2015
2025
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(4)
研究產出
(19)
相近領域學者
(6)
指紋
查看啟用 Chan-Keng Yang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Acute Heart Infarction
20%
Analysis
25%
Antibody
22%
Association
24%
Breast Cancer
20%
Cancer of Unknown Primary Origin
20%
Cell Aggregation
20%
Cell Expansion
16%
Cells
43%
Chemoradiotherapy
27%
Chronic Hepatitis C
20%
Cohort Analysis
20%
Combination Therapy
34%
Differentiation
25%
Distant Metastasis Free Survival
18%
Esophageal Cancer
40%
Experience
22%
Fluorodeoxyglucose F 18
30%
Growth
20%
Hazard Ratio
28%
Hepatocellular Carcinoma
20%
Human Leukocyte Antigen
20%
Immune Checkpoint Inhibitor
26%
Inducible Nitric Oxide Synthase
20%
Inpatient
63%
Liver
20%
Liver Failure
20%
Liver Tumor
16%
Lymph Node
20%
Maturation
20%
Metastatic Colorectal Cancer
20%
Myeloid Cell
20%
Myeloid-Derived Suppressor Cell
20%
Neoplasm
38%
Nodular Melanoma
40%
Overall Survival
38%
Paracetamol
20%
Patient
100%
Positron Emission Tomography
20%
Primary Tumor
32%
Prognostic Factor
21%
Progression Free Survival
27%
Standardized Uptake Value
40%
Survival
46%
T Cell
42%
T-Helper Cell
20%
Therapeutic Procedure
37%
Treatment Response
20%
Tumor Microenvironment
24%
Tumor Progression
17%
Immunology and Microbiology
Antineoplastic Activity
20%
Aptitude
15%
Association
20%
CD4
20%
Cell Aggregation
20%
Cell Expansion
13%
Cells
35%
Cluster of Differentiation
20%
CpG Oligodeoxynucleotide
13%
Cytokine
13%
Cytotoxic T-Cell
42%
Distant Metastasis Free Survival
15%
Growth
23%
Hepatitis C
20%
Human Leukocyte Antigen
20%
Immunity
22%
Liver
46%
Lymph Node
10%
Maturation
20%
Molecule
22%
Monospecific Antibody
22%
Mouse
9%
Myeloid
20%
Myeloid-Derived Suppressor Cell
20%
Neutrophil Granulocyte
6%
Overall Survival
23%
Phenotype
8%
Positron Emission Tomography
20%
Progression Free Survival
28%
Squamous Cell
5%
Staging
5%
Survival
20%
T Cell
18%
T Cell Receptor
5%
TLR9
6%
Viral Hepatitis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Infarction
20%
Adverse Event
5%
Antiemetic Agent
20%
Aprepitant
20%
Cancer Risk
20%
Chemotherapy
20%
Cisplatin
20%
Colon Cancer
20%
Combination Drug
5%
Dexamethasone
20%
Diseases
11%
Epidermolysis
20%
HLA B51 Antigen
8%
Liver Metastasis
5%
Malignant Neoplasm
9%
Melanoma
20%
Metastatic Colorectal Cancer
20%
Neoplasm
10%
Nivolumab
5%
Overall Survival
11%
Palonosetron
20%
Pembrolizumab
5%
Progression Free Survival
7%
